All Stories

  1. Quality of life of patients with acromegaly: comparison of different therapeutic modalities

    Article • Expert Opinion on Orphan Drugs, December 2022, Taylor & Francis

    Guenka Petrova

  2. Budget cap and pay-back model to control spending on medicines: A case study of Bulgaria

    Article • Frontiers in Public Health, November 2022, Frontiers

    Guenka Petrova

  3. Cost of arthropathic diseases therapy with biologicals disease modifying drugs (bDMARs): a 5-year cost analysis at national level

    Article • Biotechnology & Biotechnological Equipment, October 2022, Taylor & Francis

    Guenka Petrova

  4. Quality of life, control of treatment and satisfaction of patients with asthma in Bulgaria: a pilot study

    Article • Biotechnology & Biotechnological Equipment, July 2022, Taylor & Francis

    Guenka Petrova

  5. Barriers to Use Artificial Intelligence Methodologies in Health Technology Assessment in Central and East European Countries

    Article • Frontiers in Public Health, July 2022, Frontiers

    Guenka Petrova

  6. Quality of life and disease activity of patients with rheumatoid arthritis on tofacitinib and biologic disease-modifying antirheumatic drug therapies

    Article • Rheumatology International, June 2022, Springer Science + Business Media

    Guenka Petrova

  7. Challenges and Opportunities With Routinely Collected Data on the Utilization of Cancer Medicines. Perspectives From Health Authority Personnel Across 18 European Countries

    Article • Frontiers in Pharmacology, June 2022, Frontiers

    Amanj Kurdi, Guenka Petrova

  8. Pharmacist's Perspectives on Administering a COVID-19 Vaccine in Community Pharmacies in Four Balkan Countries

    Article • Frontiers in Public Health, November 2021, Frontiers

    Guenka Petrova

  9. Review of Medicine Utilization for Parkinson's Disease Management: The Bulgarian Perspective

    Article • October 2021, SAGE Publications

    Guenka Petrova

  10. Utilisation Trend of Long-Acting Insulin Analogues including Biosimilars across Europe: Findings and Implications

    Article • BioMed Research International, October 2021, Hindawi Publishing Corporation

    Amanj Kurdi, Professor Mihajlo (Michael) Jakovljevic MD, PhD, MAE, Guenka Petrova

  11. European Network to Advance Best Practices and Technology on Medication Adherence: Mission Statement

    Article • Frontiers in Pharmacology, October 2021, Frontiers

    Guenka Petrova

  12. Analysis of patients’ access to reimbursed biotechnological medicines for multiple sclerosis in Bulgaria and Greece

    Article • Expert Review of Pharmacoeconomics & Outcomes Research, September 2021, Taylor & Francis

    Guenka Petrova

  13. Do Advanced Therapies Have a Future in the Low- and Middle-Income Countries - The Case of Bulgaria, Romania, and Poland

    Article • Frontiers in Public Health, August 2021, Frontiers

    Guenka Petrova

  14. Pharmacotherapeutic Patterns and Patients’ Access to Pharmacotherapy for Some Rare Diseases in Bulgaria – A Pilot Comparative Study

    Article • Frontiers in Pharmacology, July 2021, Frontiers

    Guenka Petrova

  15. Analysis of the Household and Health Care System Expenditures in Bulgaria

    Article • Frontiers in Public Health, July 2021, Frontiers

    Guenka Petrova

  16. The Current Situation Regarding Long-Acting Insulin Analogues Including Biosimilars Among African, Asian, European, and South American Countries; Findings and Implications for the Future

    Article • Frontiers in Public Health, June 2021, Frontiers

    Amanj Kurdi, Professor Mihajlo (Michael) Jakovljevic MD, PhD, MAE, Guenka Petrova

  17. Biosimilar Insulins and Their Impact on Prices and Utilization of Insulins in Bulgaria

    Article • Healthcare, June 2021, MDPI AG

    Guenka Petrova

  18. A Cross-Sectional Survey on Medication Management Practices for Noncommunicable Diseases in Europe During the Second Wave of the COVID-19 Pandemic

    Article • Frontiers in Pharmacology, June 2021, Frontiers

    Guenka Petrova

  19. Is There a Symmetry in Disease Control and Quality of Life of Patients with Rheumatoid Arthritis Treated with Biological Therapy?

    Article • Symmetry, March 2021, MDPI AG

    Guenka Petrova

  20. A Systematic Review of Collective Evidences Investigating the Effect of Diabetes Monitoring Systems and Their Application in Health Care

    Article • Frontiers in Endocrinology, March 2021, Frontiers

    Guenka Petrova

  21. Influence of COVID-19 on Health-Related Quality of Life and the Perception of Being Vaccinated to Prevent COVID-19: An Approach for Community Pharmacists from Romania and Bulgaria

    Article • Journal of Clinical Medicine, February 2021, MDPI AG

    Guenka Petrova

  22. Potential approaches for the pricing of cancer medicines across Europe to enhance the sustainability of healthcare systems and the implications

    Article • Expert Review of Pharmacoeconomics & Outcomes Research, February 2021, Taylor & Francis

    Amanj Kurdi, Guenka Petrova

  23. Did the Introduction of Biosimilars Influence Their Prices and Utilization? The Case of Biologic Disease Modifying Antirheumatic Drugs (bDMARD) in Bulgaria

    Article • Pharmaceuticals, January 2021, MDPI AG

    Guenka Petrova

  24. Quo Vadis HTA for Medical Devices in Central and Eastern Europe? Recommendations to Address Methodological Challenges

    Article • Frontiers in Public Health, January 2021, Frontiers

    Guenka Petrova, Laszlo Lorenzovici

  25. Cost-effectiveness of in vitro fertilization and controlled ovarian hyperstimulation before and after the COVID-19 outbreak

    Article • Biotechnology & Biotechnological Equipment, January 2021, Taylor & Francis

    Guenka Petrova

  26. Triple negative breast cancer in Bulgaria: epidemiological data and treatment patterns based on real world evidence and patient registries

    Article • Biotechnology & Biotechnological Equipment, January 2021, Taylor & Francis

    Guenka Petrova

  27. Volume and trends of adalimumab and pembrolizumab reimbursed market: the Bulgarian perspective

    Article • Biotechnology & Biotechnological Equipment, January 2021, Taylor & Francis

    Guenka Petrova

  28. Health technology assessment and reimbursement policy for oncology orphan drugs in Central and Eastern Europe

    Article • Orphanet Journal of Rare Diseases, October 2020, Springer Science + Business Media

    Guenka Petrova

  29. Comparison of Cardiovascular Medicines Prices in Four European Countries

    Article • Frontiers in Public Health, August 2020, Frontiers

    Guenka Petrova

  30. Comparison of pre- and post-implantation mechanical behavior of composite hernia meshes

    Article • Journal of Theoretical and Applied Mechanics, July 2020, Polish Society of Theoretical and Applied Mechanics

    Guenka Petrova

  31. Development of transferability guidance for integrated care models with special focus on Central and Eastern European countries

    Article • Croatian Medical Journal, June 2020, Croatian Medical Journal

    Guenka Petrova

  32. Life expectancy and survival analysis of patients with diabetes compared to the non diabetic population in Bulgaria

    Article • PLoS ONE, May 2020, PLOS

    Guenka Petrova

  33. New Epidemiological, Clinical and Economic Data for Patients With Acromegaly in Bulgaria

    Article • Frontiers in Public Health, April 2020, Frontiers

    Guenka Petrova

  34. ‘Without data, you’re just another person with an opinion’

    Article • Expert Review of Pharmacoeconomics & Outcomes Research, March 2020, Taylor & Francis

    Guenka Petrova

  35. Comparative analysis of the access to health-care services and breast cancer therapy in 10 Eastern European countries

    Article • SAGE Open Medicine, January 2020, SAGE Publications

    Guenka Petrova

  36. Availability and reimbursement of biological products for severe asthma in Bulgaria

    Article • SAGE Open Medicine, January 2020, SAGE Publications

    Guenka Petrova

  37. Cardiovascular co-morbidity in patients with COPD in Bulgaria

    Article • Biotechnology & Biotechnological Equipment, January 2020, Taylor & Francis

    Guenka Petrova

  38. Аn affordability of statins therapy - comparative analysis between Ukraine and Bulgaria

    Article • BMC Health Services Research, November 2019, Springer Science + Business Media

    Guenka Petrova

  39. Pharmacotherapeutic interventions for bipolar disorder type II: addressing multiple symptoms and approaches with a particular emphasis on strategies in lower and middle-income countries

    Article • Expert Opinion on Pharmacotherapy, November 2019, Taylor & Francis

    Guenka Petrova, Philip Opondo

  40. Economic consequences of the implementation of national screening program for chronic HCV infection

    Article • Expert Review of Pharmacoeconomics & Outcomes Research, September 2019, Taylor & Francis

    Guenka Petrova

  41. Pricing of oral generic cancer medicines in 25 European countries; fi ndings and implications

    Article • Generics and Biosimilars Initiative Journal, June 2019, Pro Pharma Communications International

    Amanj Kurdi, Guenka Petrova

  42. Chronic obstructive pulmonary disease exacerbations and progression in relation to ambient air pollutants exposure

    Article • Journal of Thoracic Disease, June 2019, AME Publishing Company

    Guenka Petrova

  43. EQ-5D studies in nervous system diseases in eight Central and East European countries: a systematic literature review

    Article • The European Journal of Health Economics, May 2019, Springer Science + Business Media

    Guenka Petrova

  44. Reimbursement Legislations and Decision Making for Orphan Drugs in Central and Eastern European Countries

    Article • Frontiers in Pharmacology, May 2019, Frontiers

    Guenka Petrova

  45. PCN106 ANALYSIS OF THE COST OF ONCOHEMATOLOGY DISEASES IN BULGARIA

    Article • Value in Health, May 2019, Elsevier

    Guenka Petrova

  46. PDB73 WHAT IS THE LIFE-EXPECTANCY FOR DIABETICS IN BULGARIA?

    Article • Value in Health, May 2019, Elsevier

    Guenka Petrova

  47. BUDGET IMPACT ANALYSIS OF INHIBITOR HAEMOPHILIA A THERAPY WITH BYPASSING AGENTS

    Article • Journal of IMAB - Annual Proceeding (Scientific Papers), April 2019, Journal of IMAB

    Guenka Petrova

  48. Incretins and SGLT-2i Therapy of Type 2 Diabetes – Real Life Study of Their Therapeutic and Economic Effects

    Article • Frontiers in Pharmacology, April 2019, Frontiers

    Guenka Petrova

  49. Burden of informal care for individuals with schizophrenia and affective disorders prior to hospital admission

    Article • The European Journal of Psychiatry, April 2019, Elsevier

    Guenka Petrova

  50. Costs and outcomes for individuals with psychosis prior to hospital admission and following discharge in Bulgaria

    Article • Social Psychiatry and Psychiatric Epidemiology, March 2019, Springer Science + Business Media

    Guenka Petrova

  51. Pilot Study on the Cost of Some Oncohematology Diseases in Bulgaria

    Article • Frontiers in Public Health, March 2019, Frontiers

    Guenka Petrova

  52. Historical overview of regulatory framework development on pricing and reimbursement of medicines in Bulgaria

    Article • Expert Review of Pharmacoeconomics & Outcomes Research, March 2019, Taylor & Francis

    Guenka Petrova

  53. Proposal for a regulation on health technology assessment in Europe – opinions of policy makers, payers and academics from the field of HTA

    Article • Expert Review of Pharmacoeconomics & Outcomes Research, January 2019, Taylor & Francis

    Professor of Health Economics JOHN YFANTOPOULOS, Patricia Vella Bonanno, Guenka Petrova

  54. Cost-effectiveness analysis of current treatment of individuals with acute exacerbation of schizophrenia in Bulgaria

    Article • Biotechnology & Biotechnological Equipment, January 2019, Taylor & Francis

    Guenka Petrova, Desislava Ignatova

  55. Improved quality of diabetes control reduces complication costs in Bulgaria

    Article • Biotechnology & Biotechnological Equipment, January 2019, Taylor & Francis

    Miglena Doneva, Guenka Petrova

  56. Economic and pharmaco-economic analysis of acromegaly treatment: a systematic review

    Article • Biotechnology & Biotechnological Equipment, January 2019, Taylor & Francis

    Guenka Petrova

  57. Barriers for Access to New Medicines: Searching for the Balance Between Rising Costs and Limited Budgets

    Article • Frontiers in Public Health, December 2018, Frontiers

    Amanj Kurdi, Guenka Petrova

  58. Real World Experience of Disease Activity in Patients With Rheumatoid Arthritis and Response to Treatment With Varios Biologic DMARDs

    Article • Frontiers in Pharmacology, November 2018, Frontiers

    Guenka Petrova

  59. The European challenges of funding orphan medicinal products

    Article • Orphanet Journal of Rare Diseases, November 2018, Springer Science + Business Media

    Guenka Petrova

  60. PSY117 - ASSESSMENT OF SOCIAL AND ECONOMIC BURDEN OF CHRONIC MYELOID LEUKEMIA IN BULGARIA

    Article • Value in Health, October 2018, Elsevier

    Guenka Petrova

  61. PSY222 - HEALTH RELATED QUALITY OF LIFE (HRQOL) IN MULTIPLE MYELOMA (MM) PATIENTS IN BULGARIA

    Article • Value in Health, October 2018, Elsevier

    Guenka Petrova

  62. PSY88 - PHARMACOTHERAPY COSTS FOR PATIENTS WITH ACROMEGALY IN BULGARIA

    Article • Value in Health, October 2018, Elsevier

    Guenka Petrova

  63. PDB43 - THE COSTS AND RESULTS OF INCRETINS’AND SGLT-2I DIABETES THERAPY IN BULGARIA

    Article • Value in Health, October 2018, Elsevier

    Guenka Petrova

  64. Comparative Price Analysis of Biological Products for Treatment of Rheumatoid Arthritis

    Article • Frontiers in Pharmacology, September 2018, Frontiers

    Guenka Petrova

  65. Comparative Analysis of Legislative Requirements About Patients' Access to Biotechnological Drugs for Rare Diseases in Central and Eastern European Countries

    Article • Frontiers in Pharmacology, July 2018, Frontiers

    Guenka Petrova

  66. Quality of Life and Cost Study of Rheumatoid Arthritis Therapy With Biological Medicines

    Article • Frontiers in Pharmacology, July 2018, Frontiers

    Guenka Petrova

  67. Medical, social, and economic consequences of type 2 diabetes therapy with medicinal products from the group of DPP-4i, SGLT-2i, and GLP-1 RA

    Article • International Journal of Diabetes in Developing Countries, June 2018, Springer Science + Business Media

    Guenka Petrova

  68. FRI0039 Measuring health realted quality of life (EQ-5D) in patients with rheumatoid arthritis after one year treatment with csdmards and biologic dmards

    Article • June 2018, BMJ

    Guenka Petrova

  69. EQ-5D studies in cardiovascular diseases in eight Central and Eastern European countries: a systematic review of the literature

    Article • Kardiologia Polska, May 2018, Polskie Towarzystwo Kardiologiczne

    Guenka Petrova

  70. An Overview of the Reimbursement Decision-Making Processes in Bulgaria As a Reference Country for the Middle-Income European Countries

    Article • Frontiers in Public Health, March 2018, Frontiers

    Guenka Petrova

  71. Rationalizing the introduction and use of pharmaceutical products: The role of managed entry agreements in Central and Eastern European countries

    Article • Health Policy, March 2018, Elsevier

    Guenka Petrova

  72. Patient Access, Unmet Medical Need, Expected Benefits, and Concerns Related to the Utilisation of Biosimilars in Eastern European Countries: A Survey of Experts

    Article • BioMed Research International, January 2018, Hindawi Publishing Corporation

    Guenka Petrova, Marcell Csanádi, prof Vitaly Vladimirovich Omelyanovskiy , Laszlo Lorenzovici

  73. Assessment of the social and economic burden of glaucoma in Bulgaria

    Article • Biomedical Research, January 2018, OMICS Publishing Group

    Guenka Petrova

  74. Screening and diagnosis of chronic HCV infection in Bulgaria: A review of the current practice

    Article • Biomedical Research, January 2018, OMICS Publishing Group

    Guenka Petrova

  75. Statins utilization and price variations-comparison between Ukraine and Bulgaria

    Article • Biomedical Research, January 2018, OMICS Publishing Group

    Guenka Petrova

  76. Orphan medicinal products’ access to the Bulgarian pharmaceutical market – challenges and obstacles

    Article • Expert Opinion on Orphan Drugs, December 2017, Taylor & Francis

    Guenka Petrova

  77. Policies for biosimilar uptake in Europe: An overview

    Article • PLoS ONE, December 2017, PLOS

    Guenka Petrova

  78. Pharmaceutical Regulation in Central and Eastern European Countries: A Current Review

    Article • Frontiers in Pharmacology, December 2017, Frontiers

    Dr. Adina Turcu-Stiolica, Guenka Petrova

  79. Analysis Of Health-Related Quality Of Life (HRQOL), And Costs Of Treatment In Chronic Myelogenic Leukemia (CML) In Bulgaria

    Article • Value in Health, October 2017, Elsevier

    Guenka Petrova

  80. Estimating The Cost of Diabetes-Related Cardiovascular Complications In Selected Central And Eastern European Countries

    Article • Value in Health, October 2017, Elsevier

    Guenka Petrova

  81. Generic Competition and ITS Impact on Reference Pricing System and Medicnes Utilization in the Group of Sartans

    Article • Value in Health, October 2017, Elsevier

    Guenka Petrova

  82. Inhaled corticosteroids in stable COPD – international recommendations and reality in Bulgaria

    Article • September 2017, European Respiratory Society (ERS)

    Guenka Petrova

  83. EQ-5D studies in musculoskeletal and connective tissue diseases in eight Central and Eastern European countries: a systematic literature review and meta-analysis

    Article • Rheumatology International, August 2017, Springer Science + Business Media

    Guenka Petrova

  84. Adaptive Pathways: Possible Next Steps for Payers in Preparation for Their Potential Implementation

    Article • Frontiers in Pharmacology, August 2017, Frontiers

    Guenka Petrova

  85. The Implementation of Managed Entry Agreements in Central and Eastern Europe: Findings and Implications

    Article • PharmacoEconomics, August 2017, Springer Science + Business Media

    Guenka Petrova

  86. Chronic Hepatitis C-Related Cirrhosis Hospitalization Cost Analysis in Bulgaria

    Article • Frontiers in Medicine, August 2017, Frontiers

    Guenka Petrova

  87. Pricing and Reimbursement of Biosimilars in Central and Eastern European Countries

    Article • Frontiers in Pharmacology, June 2017, Frontiers

    Dr. Adina Turcu-Stiolica, Guenka Petrova

  88. Assessment of the expectancy, seriousness and severity of adverse drug reactions reported for chronic obstructive pulmonary disease therapy

    Article • SAGE Open Medicine, January 2017, SAGE Publications

    Guenka Petrova

  89. Clinical characteristics, treatment patterns, and socio-economic burden of COPD in Bulgaria

    Article • Journal of Medical Economics, January 2017, Taylor & Francis

    Guenka Petrova

  90. Efficacy and Safety of Reimbursed Orphan Medicines in Bulgaria – Systematic Review and Meta-analysis (Part I)

    Article • Journal of Pharmaceutical Research International, January 2017, Sciencedomain International

    Guenka Petrova

  91. Cost-effectiveness of different types of COH protocols for in vitro fertilization at national level

    Article • Biotechnology & Biotechnological Equipment, December 2016, Taylor & Francis

    Guenka Petrova

  92. Annual Cost Аnalysis for Medicinal Products for Rare Diseases in Bulgaria

    Article • Value in Health, November 2016, Elsevier

    Guenka Petrova

  93. Budget And Patient Access Analysis To Second Line Therapy Of Multiple Sclerosis In Bulgaria

    Article • Value in Health, November 2016, Elsevier

    Guenka Petrova

  94. Cost Analysis of Therapy with Idursulfase For Hunter Syndrome In Bulgaria

    Article • Value in Health, November 2016, Elsevier

    Guenka Petrova

  95. EQ-5D Studies in Diseases of The Circulatory System in Eight Central and Eastern European Countries

    Article • Value in Health, November 2016, Elsevier

    Guenka Petrova

  96. Eq-5d Studies In Nervous System Diseases In Eight Central And Eastern European Countries

    Article • Value in Health, November 2016, Elsevier

    Guenka Petrova

  97. EQ-5D Studies in Rheumatology in Eight Central and Eastern European Countries

    Article • Value in Health, November 2016, Elsevier

    Guenka Petrova

  98. Estimation of The Direct Cost of COPD In Bulgaria

    Article • Value in Health, November 2016, Elsevier

    Guenka Petrova

  99. Impact of Generic Competition on Changes in Reference Price Per Ddd and Medicnes Utilization in the Group of Statins

    Article • Value in Health, November 2016, Elsevier

    Guenka Petrova

  100. Mapping of The Biosimilar Drug Policy in 10 Central Eastern European Countries

    Article • Value in Health, November 2016, Elsevier

    Guenka Petrova, Laszlo Lorenzovici

  101. Relations between Adherence to Therapy and Quality of Life (Qol) In Cml Patients in Bulgaria

    Article • Value in Health, November 2016, Elsevier

    Guenka Petrova

  102. EQ-5D in Central and Eastern Europe: 2000–2015

    Article • Quality of Life Research, July 2016, Springer Science + Business Media

    Guenka Petrova

  103. Generic policy in Bulgaria: a policy of failure or success?

    Article • Biotechnology & Biotechnological Equipment, July 2016, Taylor & Francis

    Guenka Petrova

  104. Cost of severe hypoglycaemia in nine European countries

    Article • Journal of Medical Economics, June 2016, Taylor & Francis

    Guenka Petrova

  105. Assesment of the Medical and Social Benefits of Incretin-Based Therapy

    Article • Value in Health, May 2016, Elsevier

    Guenka Petrova

  106. Copd Pharmacotherapy In Bulgaria And Its Adherence To Gold Guidelines

    Article • Value in Health, May 2016, Elsevier

    Guenka Petrova

  107. Meta-Analysis For Orphan Drugs: An Example With Bosutinib

    Article • Value in Health, May 2016, Elsevier

    Guenka Petrova

  108. Cost-effectiveness of short COH protocols with GnRH antagonists using different types of gonadotropins forin vitrofertilization

    Article • Biotechnology & Biotechnological Equipment, March 2016, Taylor & Francis

    Guenka Petrova

  109. A Novel Method for Calculating Medication Adherence to Poly-Pharmacotherapy by Linking General Practice Prescribing Data and Pharmacy Dispensing Records

    Article • Value in Health, November 2015, Elsevier

    Guenka Petrova

  110. A Pilot Study of Direct Costs for Patients With Rheumatoid Arthritis In Bulgaria

    Article • Value in Health, November 2015, Elsevier

    Guenka Petrova

  111. Assessment of Compliance among Patients with Arthritis

    Article • Value in Health, November 2015, Elsevier

    Guenka Petrova

  112. Assessment of Unmet Healthcare Needs In Diabetic Patients In Bulgaria

    Article • Value in Health, November 2015, Elsevier

    Guenka Petrova

  113. Analysis of The Cost of Invasive Fungal Infections In Patients With Hemopoetic Stem Cell Transplantation

    Article • Value in Health, November 2015, Elsevier

    Guenka Petrova

  114. Cost Analysis of The Chronic Hcv-Related Cirrhosis In Bulgaria

    Article • Value in Health, November 2015, Elsevier

    Guenka Petrova

  115. New Copd Medicinal Products Entrance Analysis And Their Influence On The Number And Cost Of Hospitalizatons Due To Copd Exacerbations

    Article • Value in Health, November 2015, Elsevier

    Guenka Petrova

  116. Pharmacoeconomic Guideline for Positive Drug List Application Purposes Implemented In Bulgaria

    Article • Value in Health, November 2015, Elsevier

    Guenka Petrova

  117. Social Burden of Chronic Hcv Infection in Patients with Hepatocellular Carcinoma

    Article • Value in Health, November 2015, Elsevier

    Guenka Petrova

  118. Generics and fixed-dose combinations in cardiology: satisfaction analysis of pharmacists and cardiologists

    Article • Biotechnology & Biotechnological Equipment, October 2015, Taylor & Francis

    Guenka Petrova

  119. Use of biologics for psoriasis in Central and Eastern European countries

    Article • Journal of the European Academy of Dermatology and Venereology, September 2015, Wiley

    Guenka Petrova

  120. Cost-Minimization Analysis of Direct Cost of Sevelamer Carbonate and Lanthanum Carbonate in the Treatment of Patients with Chronic Kidney Disease Not on Dialysis in Bulgaria

    Article • Value in Health Regional Issues, September 2015, Elsevier

    Guenka Petrova

  121. Cost of hospitalizations due to microvascular and macrovascular complications in type 1 and type 2 diabetic patients in Bulgaria

    Article • Biotechnology & Biotechnological Equipment, May 2015, Taylor & Francis

    Guenka Petrova

  122. Health technology assessment in the Balkans: opportunities for a balanced drug assessment system

    Article • Biotechnology & Biotechnological Equipment, November 2014, Taylor & Francis

    Guenka Petrova

  123. A Cost-Effectiveness Analysis of Different Types of Labor for Singleton Pregnancy – Real Life Data

    Article • Value in Health, November 2014, Elsevier

    Guenka Petrova

  124. Assessment of Effect of Continuous Subcutaneous Insulin Infusion Treatment, Insulin Analog And Human Insulin of Children With Diabetes

    Article • Value in Health, November 2014, Elsevier

    Guenka Petrova

  125. Budget Impact Analysis of Adding Dapaglifozin To The Therapy of Diabetes Mellitus Type 2 In Bulgaria

    Article • Value in Health, November 2014, Elsevier

    Guenka Petrova

  126. COST- MINIMIZATION ANALYSIS OF THE DIRECT COSTS OF SEVELAMER CARBONATE AND LANTHANUM CARBONATE IN THE TREATMENT OF CKD-ND PATIENTS

    Article • Value in Health, November 2014, Elsevier

    Guenka Petrova

  127. Cost- Effectiveness of Real Life Asthma Pharmacotherapy

    Article • Value in Health, November 2014, Elsevier

    Guenka Petrova

  128. Evaluation of The Impact of Pharmaceutical Cognitive Service on Quality of Life in Diabetic Patients

    Article • Value in Health, November 2014, Elsevier

    Guenka Petrova, Emilia Krassimirova Naseva

  129. Economic Evaluation of Vaccination Against Hav in High Risk Population

    Article • Value in Health, November 2014, Elsevier

    Guenka Petrova

  130. Pharmacoeconomic Evaluation For Reimbursement Purposes in Bulgaria: Recent Updates

    Article • Value in Health, November 2014, Elsevier

    Guenka Petrova

  131. Comparison of health-related quality-of-life measurement instruments in diabetic patients

    Article • Biotechnology & Biotechnological Equipment, July 2014, Taylor & Francis

    Guenka Petrova, Emilia Krassimirova Naseva

  132. Humanistic and economic aspects of haemophilia treatment in Bulgaria. Comparison between two therapeutic approaches: prophylactic vs. on-demand treatment

    Article • Biotechnology & Biotechnological Equipment, May 2014, Taylor & Francis

    Guenka Petrova

  133. Health technology assessment in Poland, the Czech Republic, Hungary, Romania and Bulgaria

    Article • The European Journal of Health Economics, May 2014, Springer Science + Business Media

    Guenka Petrova

  134. Transferability Of International Evidence On The Benefits Of Innovative Medicines Into Central Eastern European Countries

    Article • Value in Health, May 2014, Elsevier

    Guenka Petrova

  135. Economic consequences of the vaccination against hepatitis A in the Bulgarian healthcare setting

    Article • Biotechnology & Biotechnological Equipment, March 2014, Taylor & Francis

    Guenka Petrova

  136. ISO 9001 certification for hospitals in Bulgaria: does it help service?

    Article • Biotechnology & Biotechnological Equipment, March 2014, Taylor & Francis

    Guenka Petrova

  137. Cost-effectiveness analysis of different types of labor for singleton pregnancy: Real life data

    Article • Srpski arhiv za celokupno lekarstvo, January 2014, National Library of Serbia

    Guenka Petrova

  138. Benefits of investment into modern medicines in Central–Eastern European countries

    Article • Expert Review of Pharmacoeconomics & Outcomes Research, December 2013, Taylor & Francis

    Guenka Petrova

  139. Costs of Alternative Methods of Child Delivery in Serbia

    Article • Value in Health, November 2013, Elsevier

    Guenka Petrova

  140. Regulatory and General Epidemiological Knowledge About Rare Diseases and Access to Treatment for Rare Diseases: Health Professionals’ View in Serbia

    Article • Value in Health, November 2013, Elsevier

    Dr sc.med. Dragana Jocic, Guenka Petrova

  141. Can We Use the EQ-5D Only for Assessing the Quality of Life of Patients with Osteoporosis?

    Article • Value in Health, November 2013, Elsevier

    Guenka Petrova

  142. Cost of Microvascular and Macrovascular Complications in Peoples with Diabetes Type 1 and Type 2 in Bulgaria

    Article • Value in Health, November 2013, Elsevier

    Guenka Petrova

  143. Comparative Analysis of the Cost and Metabolic Control in Diabetic Children Using Insulin Pumps

    Article • Value in Health, November 2013, Elsevier

    Guenka Petrova

  144. Health Economic Analysis of Pneumococcal Vaccination – Example from Bulgaria

    Article • Value in Health, November 2013, Elsevier

    Guenka Petrova

  145. Patients as a Source for Cost of Rheumatoid Arthritis Study

    Article • Value in Health, November 2013, Elsevier

    Guenka Petrova

  146. Pharmaco-Economic Education Needs Investigated by ISPOR Chapter – Example from Bulgaria

    Article • Value in Health, November 2013, Elsevier

    Guenka Petrova

  147. Pricing and Reimbursement Analysis of Lifestyle Medicines in Serbia

    Article • Value in Health, November 2013, Elsevier

    Guenka Petrova

  148. Study of Quality of Life and Costs for CML Patients in Bulgaria

    Article • Value in Health, November 2013, Elsevier

    Guenka Petrova

  149. Economic evaluation of continuous subcutaneous insulin infusion for children with diabetes - a pilot study: CSII application for children – economic evaluation

    Article • BMC Pediatrics, October 2013, Springer Science + Business Media

    Guenka Petrova

  150. Abstracts 8th working conference of the pharmaceutical care network Europe, 6–8 February 2013, Berlin, Germany

    Article • International Journal of Clinical Pharmacy, April 2013, Springer Science + Business Media

    Guenka Petrova

  151. Use of complementary and alternative medicine by children in Europe: Published data and expert perspectives

    Article • Complementary Therapies in Medicine, April 2013, Elsevier

    Prof ADAMOS HADJIPANAYIS, Guenka Petrova

  152. A Cross-Country Comparison of Reimbursed Orphan Medicines in Bulgaria, Greece and Romania

    Article • Biotechnology & Biotechnological Equipment, January 2013, Taylor & Francis

    Guenka Petrova

  153. A HEALTH-RELATED QUALITY OF LIFE AND PHARMACOTHERAPY COSTS STUDY FOR PATIENTS WITH CYSTIC FYBROSIS, GAUCHER DISEASE AND CHRONIC MYELOID LEUKEMIA IN BULGARIA

    Article • Biotechnology & Biotechnological Equipment, January 2013, Taylor & Francis

    Guenka Petrova

  154. Budget Impact Analysis of Chronic Myeloid Leukemia Treatment in Bulgaria

    Article • Biotechnology & Biotechnological Equipment, January 2013, Taylor & Francis

    Guenka Petrova

  155. Comparative Analysis of the Cost of Insulin Treated Patients in Bulgaria

    Article • Biotechnology & Biotechnological Equipment, January 2013, Taylor & Francis

    Guenka Petrova

  156. Complex Regional Pain Syndrome Acceptance and the Alternative Denominations in the Medical Literature

    Article • Medical Principles and Practice, January 2013, Karger Publishers

    Guenka Petrova

  157. Economic evaluation of diff erent screening alternatives for patients with clinically suspected acute deep vein thrombosis

    Article • Biochemia Medica, January 2013, Croatian Society for Medical Biochemistry and Laboratory Medicine

    Guenka Petrova

  158. Economic Impact of the Highly Active Antiretroviral Pharmacotherapy on Cost and HIV/AIDS Control in Bulgaria

    Article • Biotechnology & Biotechnological Equipment, January 2013, Taylor & Francis

    Guenka Petrova

  159. Enantiomers Novelty Protection and its Influence on Generic Market: An Example with Escitalopram Patent Protection

    Article • Biotechnology & Biotechnological Equipment, January 2013, Taylor & Francis

    Guenka Petrova

  160. Quality Management in Pharmaceutical Procurement: Most Frequent Non-Conformities in Pharmaceutical Wholesalers in Bulgaria

    Article • Biotechnology & Biotechnological Equipment, January 2013, Taylor & Francis

    Guenka Petrova

  161. How much do we pay for caesarean section: A pilot study in Serbia

    Article • Acta chirurgica iugoslavica, January 2013, National Library of Serbia

    Guenka Petrova

  162. Article • International Journal of Pharmaceutical Sciences and Research, January 2013, International Journal of Pharmaceutical Sciences and Research

    Guenka Petrova

  163. Double Celebration: Two Notable Bulgarian Academicians and Co-Founders of Diagnosis Press™ Turned 70 this Year

    Article • Biotechnology & Biotechnological Equipment, January 2013, Taylor & Francis

    Guenka Petrova

  164. PHS87 Cost of Diabetes in Insulin-Treated Patients in Bulgaria

    Article • Value in Health, November 2012, Elsevier

    Guenka Petrova

  165. PGI39 Budegt Impact Analysis of HCV Therapy Cost After Boceprevir Addition to Standard Therapeutic Regime

    Article • Value in Health, November 2012, Elsevier

    Guenka Petrova

  166. PCV40 Pharmacotherapy Cost of Patients With Hypertension in Bulgaria

    Article • Value in Health, November 2012, Elsevier

    Guenka Petrova

  167. PHP137 Changes in the Medicines Pricing and Reimbursement Approach in Bulgaria

    Article • Value in Health, November 2012, Elsevier

    Guenka Petrova

  168. PSY13 Pilot Cost Study of Chronic Mieloid Leukemia Therapy

    Article • Value in Health, November 2012, Elsevier

    Guenka Petrova

  169. PIN36 Six Years Observational Study of the Cost of Highly Active Antiretroviral Therapy and HIV/AIDS Control

    Article • Value in Health, November 2012, Elsevier

    Guenka Petrova

  170. PMD41 Economic Evaluation of Continuous Subcutaneous Insulin Infusion for Children With Diabetes – a Pilot Study

    Article • Value in Health, November 2012, Elsevier

    Guenka Petrova

  171. Safety aspects of chronic myeloid leukemia pharmacotherapy

    Article • African Journal of Pharmacy and Pharmacology, February 2012, Academic Journals

    Guenka Petrova

  172. Pharmacy network and access to medicines in selected eastern European countries: comparative analysis

    Article • Croatian Medical Journal, February 2012, Croatian Medical Journal

    Guenka Petrova

  173. Chirality as a Patent Protection Policy—An Example with Citalopram

    Article • Biotechnology & Biotechnological Equipment, January 2012, Taylor & Francis

    Assoc.Prof. Ivanka P Pencheva - El Tibi, Guenka Petrova

  174. Cost-Effectiveness of Biphasic Insulin Aspart 30 VS. Human Premix Insulin in Type 2 Diabetes from the Payer's Perspective in Bulgaria

    Article • Biotechnology & Biotechnological Equipment, January 2012, Taylor & Francis

    Guenka Petrova

  175. Economic Analysis 20 Years after the Introduction of Universal HBV Immunisation in Bulgaria

    Article • Biotechnology & Biotechnological Equipment, January 2012, Taylor & Francis

    Guenka Petrova

  176. Pharmaceutical Biotechnology Education in the Pharmacy Curriculum at European Universities

    Article • Biotechnology & Biotechnological Equipment, January 2012, Taylor & Francis

    Guenka Petrova

  177. The Cost-Effectiveness of Hypertension Pharmacotherapy in Serbia: A Markov Model

    Article • Biotechnology & Biotechnological Equipment, January 2012, Taylor & Francis

    Guenka Petrova

  178. The Health Related Quality of Life for Kidney Transplant Patients in Bulgaria—A Pilot Study

    Article • Biotechnology & Biotechnological Equipment, January 2012, Taylor & Francis

    Guenka Petrova

  179. PCN27 Budget Impact Analysis for Chronic Mieloid Leukemia Therapy in Bulgaria

    Article • Value in Health, November 2011, Elsevier

    Guenka Petrova

  180. PDB29 Modeling the Impact of Enhanced Treatment of Type 2 Diabetes Mellitus in Bulgaria

    Article • Value in Health, November 2011, Elsevier

    Guenka Petrova

  181. PDB75 Analysis of the Medicines Pricing Procedure in the Republic of Macedonia

    Article • Value in Health, November 2011, Elsevier

    Guenka Petrova

  182. PIH62 Comparative Pricing and Reimbursement Analysis in Four East European Countries

    Article • Value in Health, November 2011, Elsevier

    Guenka Petrova

  183. PIN33 Economic Impact of the Antiretroviral Pharmacotherapy on Cost and HIV/AIDS Control in Bulgaria

    Article • Value in Health, November 2011, Elsevier

    Guenka Petrova

  184. PUK7 3 Years Follow Up of the Pharmacotherapy Cost of Patients with Kidney Transplantation in Bulgaria

    Article • Value in Health, November 2011, Elsevier

    Guenka Petrova

  185. PMS20 Treatment of Patients with Moderate and Severe Psoriasis – Cost-of-Illness in the Czech Republic

    Article • Value in Health, November 2011, Elsevier

    Guenka Petrova

  186. Budget Impact Model of New Antiretroviral Biotechnology Medicines for Treatment of HIV/AIDS Patients in Bulgaria

    Article • Biotechnology & Biotechnological Equipment, January 2011, Taylor & Francis

    Guenka Petrova

  187. Impact of Discounting in Pharmacoeconomic Modeling. A Case Study

    Article • Biotechnology & Biotechnological Equipment, January 2011, Taylor & Francis

    Guenka Petrova

  188. Patent Protection Policy in the Therapeutic Group of Statins

    Article • Biotechnology & Biotechnological Equipment, January 2011, Taylor & Francis

    Guenka Petrova

  189. Pharmaceutical Biotechnology in Pharmacy Education: USA Pharmacy Schools

    Article • Biotechnology & Biotechnological Equipment, January 2011, Taylor & Francis

    Guenka Petrova

  190. Reimbursed Orphan Medicines in Bulgaria and the Share of Biotechnology-Derived Products

    Article • Biotechnology & Biotechnological Equipment, January 2011, Taylor & Francis

    Guenka Petrova

  191. Utilization and Price Trends in Some Reimbursed Cardiovascular Medicines

    Article • Biotechnology & Biotechnological Equipment, January 2011, Taylor & Francis

    Guenka Petrova

  192. PDB61 ECONOMIC EVALUATION OF LIRAGLUTIDE VS. ROSIGLITAZONE OR EXENATIDE FOR TYPE 2 DIABETES MELLITUS IN BULGARIA

    Article • Value in Health, November 2010, Elsevier

    Guenka Petrova

  193. Impact of generic competition on market share and prices of cardiovascular medicines on the Bulgarian pharmaceutical market

    Article • Journal of Public Health, July 2010, Springer Science + Business Media

    Guenka Petrova

  194. PHP61 POSITIVE DRUG LIST IN BULGARIA—5 YEARS LATER

    Article • Value in Health, October 2009, Elsevier

    Guenka Petrova

  195. PIN11 BUDGET IMPACT ANALYSIS OF NEW ANTRIRETROVIRAL MEDICINES FOR TREATMENT OF HIV PATIENTS IN BULGARIA

    Article • Value in Health, October 2009, Elsevier

    Guenka Petrova

  196. PUK7 ANALYSIS OF THE PHARMACOTHERAPY COST OF PATIENTS WITH KIDNEY TRANSPLANTATION IN BULGARIA

    Article • Value in Health, October 2009, Elsevier

    Guenka Petrova

  197. Cost of outpatient hypertension pharmacotherapy: comparative study between Bulgaria and Serbia

    Article • June 2009, Instituto de Salud Carlos III/BNCS/SciELO Espana

    Guenka Petrova

  198. The applicability of the tetraclass model to the management of the patient satisfaction in the pharmacies

    Article • March 2009, Instituto de Salud Carlos III/BNCS/SciELO Espana

    Guenka Petrova

  199. PCV33 COST OF OUTPATIENT HYPERTENSION PHARMACOTHERAPY—COMPARATIVE STUDY BETWEEN BULGARIA AND SERBIA

    Article • Value in Health, November 2008, Elsevier

    Guenka Petrova

  200. Evaluation of consumer satisfaction using the tetra-class model

    Article • Research in Social and Administrative Pharmacy, September 2008, Elsevier

    Guenka Petrova

  201. Low fresh gas flow balanced anesthesia versus target controlled intravenous infusion anesthesia in laparoscopic cholecystectomy: A cost-minimization analysis

    Article • Clinical Therapeutics, September 2008, Elsevier

    Guenka Petrova

  202. PHP56 COMPARATIVE ANALYSIS OF THE ACCESS TO PHARMACEUTICALS IN SELECTED EAST EUROPEAN COUNTRIES

    Article • Value in Health, May 2008, Elsevier

    Guenka Petrova

  203. Safety Assessment of Newly Marketed Herbal Medicines—Methodological Approach (Ginkgo bilobaExample in Bulgaria)

    Article • Journal of Herbal Pharmacotherapy, January 2008, Taylor & Francis

    Guenka Petrova

  204. Cost-effectiveness analysis in diagnosis of coronary artery disease: Choice of laboratory markers

    Article • Clinical Biochemistry, November 2007, Elsevier

    Guenka Petrova

  205. PCV40 STUDY OF THE COST OF OUTPATIENT HYPERTENSION THERAPY IN BULGARIA

    Article • Value in Health, November 2007, Elsevier

    Guenka Petrova

  206. PCV74 COST-EFFECTIVENESS ANALYSIS IN CORONARY ARTERY DISEASE DIAGNOSIS: CHOOSING BETWEEN LABORATORY MARKERS

    Article • Value in Health, November 2006, Elsevier

    Guenka Petrova

  207. Pilot project for education of patients with type 2 diabetes by pharmacists

    Article • Acta Diabetologica, August 2006, Springer Science + Business Media

    Guenka Petrova

  208. PHP16 PHARMACOECONOMICS INTRODUCTION IN THE CREATION OF POSITIVE DRUG LIST IN BULGARIA

    Article • Value in Health, November 2004, Elsevier

    Guenka Petrova